Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy

European Journal of Ophthalmology

Volumn 22, Issue 5, 2012, Pages 792-798

  Davidović, Sofija P ^a   Nikolić, Stanislava V ^b   Ćurić, Nikola J ^b   Latinović, Slobodanka L J ^a   Drašković, Dragan O ^b   Čabarkapa, Velibor S ^b   Stošić, Zoran Z ^b  

^a University Eye Clinic   (Serbia)

^b CLINICAL CENTER OF VOJVODINA   (Serbia)

Author keywords

Diabetic retinopathy; Vascular endothelial growth factor inhibitors

Indexed keywords

BEVACIZUMAB; INSULIN; PROXYMETACAINE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INSULIN TREATMENT; LASER COAGULATION; MALE; PATIENT SELECTION; PILOT STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA MACULA EDEMA; SINGLE DRUG DOSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863317107     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000118     Document Type: Article

References (22)

1. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1-29.
2. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006; 26: 512-8.
3. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726-33.
4. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006; 2: 71-98.
5. Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004; 61(Suppl 5): S21-6.
6. Barkmeier AJ, Akduman L. Bevacizumab (Avastin) in ocular processes other than choroidal neovascularization. Ocul Immunol Inflamm 2009; 17: 109-17.
7. Waisbourd M, Goldstein M, Loewenstein A. Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Ophthalmol 2011; 89: 203-7.
8. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56: 95-113.
9. Ota M, Tsujikawa A, Miyamoto K, Sakamoto A, Murakami T, Yoshimura N. Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion. Jpn J Ophthalmol 2010; 54: 555-64.
10. Campbell RJ, Bronskill SE, Bell CM, Paterson JM, Whitehead M, Gill SS. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol 2010; 128: 359-62.
11. Frenkel RE, Haji SA, La M, Frenkel MP, Reyes A. A protocol for the retina surgeon's safe initial intravitreal injections. Clin Ophthalmol 2010; 4: 1279-85.
12. van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011; 31: 1449-69.
13. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010; 51: 1606-8.
14. Ameri H, Chader GJ, Kim JG, Sadda SR, Rao NA, Humayun MS. The effects of intravitreous bevacizumab on retinal neo vascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 2007; 48: 5708-15.
15. Sato T, Wada K, Arahori H, Kuno N et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol Epub 2011 Sep 17.
16. Heiduschka P, Fietz H, Hofmeister S, et al; Tubingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-23.
17. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146: 508-12.
18. Stahl A, Buchwald A, Martin G, et al. Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina 2010; 30: 1524-9.
19. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of Intravitreal Bevacizumab (Avastin). Ophthalmology 2007; 114: 855-9.
20. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94: 1215-8.
21. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009; 50: 4807-13.
22. Chuang LH, Wu WC, Yeung L, et al. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion. Ophthalmic Res 2011; 45: 31-5.